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Improving postoperative pain control after cesarean delivery
with enhanced recovery in patients on buprenorphine therapy
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ABSTRACT
I ntroduction: Prescription drug abuse presents a significant challenge to the
management of postoperative pain. Pain control amongst the opioid addicted patient
can be especially challenging. We aimed to improve pain control after cesarean delivery
with enhanced recovery in patients who are on buprenorphine medication-assisted
therapy for the treatment of opioid addiction.
Materials and Methods: We conducted a pilot study by implementing a protocol using
liposomal bupivacaine injected at the time of cesarean delivery. Patients were then
given 500mg oral acetaminophen every 4 hours, 800mg oral ibuprofen every 8 hours
and 0.3mg IV buprenorphine every 6 hours as needed. Patients’ maintenance dosing of
buprenorphine was divided into doses throughout the day. In addition, patients were
ambulated 4 hours after surgery and had their catheters removed from their bladder as
soon as they could safely ambulate. Eleven patients were prospectively recruited and
then compared to a retrospective sample of seventeen patients.
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Results : Patients in the treatment group reported 27% lower pain scores (p<0.05)
with 55% and 100% achieving a mean pain score 3 and 4 or less, respectively
(p<0.05). Patients who were in the treatment group utilized 51% less breakthrough
IV buprenorphine with 45% declining IV buprenorphine, however these did reach
statistical significance. Hospital charges were reduced by $1,589 (p<0.01).
Discussion: Our enhanced recovery protocol is an effective alternative to traditional pain
control and is associated with a significant reduction in both pain scores and use of
breakthrough IV buprenorphine as well as lower charges.
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INTRODUCTION
Prescription drug abuse creates a significant problem
in the United States. With 41.5 overdoses per 100,000,
West Virginia has among the highest overdose rates
in the country.1 Buprenorphine is an approved form
of medication-assisted therapy and is recommended
for the treatment of addiction in pregnancy.2 Pain
control for this patient population can be especially
challenging, as literature regarding this subject is
lacking. Further complicating pain management in
this population is the high opioid maintenance dose
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utilized by this population. Using standard opioid
conversion ratio of 1mg sublingual buprenorphine
to 10mg oral morphine,3,4 a patient taking 16mg
daily of sublingual buprenorphine is already taking
160mg opioid daily. For comparison, this is the
same as taking 21 oxycodone 5mg tablets, 8mg of
IV hydromorphone, 53mg of IV morphine or 533mcg
of IV fentanyl daily.3,4 Cesarean delivery accounts
for 31% of all deliveries, making it one of the most
common operations on reproductive age women.5
This therefore necessitates evaluation of postcesarean pain protocols.
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Certain protocols have been developed specifically
to help patients recover more rapidly after surgery.
Enhanced Recovery after Surgery (ERAS) protocols
utilize multimodal pain control and local anesthesia
combined with early feeding, ambulation and
catheter removal to expedite patient recovery.6-12
Several studies have shown that ERAS protocols
improve patient pain control and increase patient
satisfaction while decreasing opioid use.6-12
Liposomal bupivacaine is a formulation of the local
anesthetic bupivacaine that has been encapsulated
by lipids in order to increase the effective duration
of the drug by several days.13 One study found
that using liposomal bupivacaine along with ERAS
protocols decreased length of stay following a
cesarean delivery without any increase in adverse
events.6
There is a paucity of data evaluating any manner
of pain control after cesarean delivery in patients
who struggle with opioid addiction, let alone those
on buprenorphine medication-assisted therapy.
Data evaluating liposomal bupivacaine is limited
to the aforementioned study. We hypothesize that
implementation of an ERAS protocol that utilizes
liposomal bupivacaine at the time of surgery
will improve pain control and decrease the use
of IV buprenorphine for breakthrough pain in
patients undergoing a cesarean delivery who are
in opioid-addiction recovery programs that utilize
buprenorphine for medication-assisted therapy.
MATERIALS AND METHODS
We conducted an ambispective pilot study to
evaluate postoperative pain management strategies.
This started with a retrospective analysis of the
current standard of care. At our institution, patients
who undergo scheduled cesarean delivery receive
spinal anesthesia consisting of 13mg bupivacaine,
10mcg of fentanyl and 0.2mg morphine. Currently, in
addition to the On-Q® and continuing current home
maintenance buprenorphine dose as scheduled,
patients receive IV ketorolac 30mg every 6 hours
followed by 10mg oral ketorolac every 6 hours, as
well as 0.3mg IV buprenorphine every 6 hours as
needed. The On-Q® system utilizes percutaneous
catheters that infiltrate the abdominal and pelvic
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cavities with buprenorphine over a 2 to 3 day period.
After surgery, patients are allowed regular diet 1
hour after surgery. The catheter is removed after
12 to 24 hours and patient is allowed to ambulate
12 hours after surgery. The retrospective analysis
included patients within given time period that met
inclusion criteria.
Next, we prospectively implemented an ERAS
protocol previously described in gynecologic
oncology literature.13 This protocol consisted of the
spinal anesthesia, as mentioned above, followed
by 266mg (20mL) diluted into an additional 20 mL
of normal saline of liposomal bupivacaine injected
subcutaneously along the length of the incision
at time of skin closure. Postoperative pain was
controlled with 500mg of oral acetaminophen
scheduled every 4 hours, 800mg of oral ibuprofen
every 8 hours and 0.3mg IV buprenorphine
every 6 hours as needed for breakthrough pain.
Maintenance buprenorphine dose was then divided
into 4 times daily dosing. For example, if a patient
takes 16mg daily of buprenorphine then they would
receive 4mg every 6 hours postoperatively. Patients
resumed regular diet 1 hour after surgery. In
addition, patients were ambulated after 4 hours and
the catheter was removed when the patient could
safely ambulate.
We compared the retrospective data, which reflected
the standard of care, to the data we collected
prospectively following the implementation of the
ERAS protocol. For the retrospective analysis, we
included all eligible patients over a 1-year span. To
be eligible for inclusion in the retrospective group,
patients had to be at an age of 18 years or greater,
at a gestational age of 34 weeks or greater, and
have a non-emergent cesarean delivery at Cabell
Huntington Hospital while being treated for opioid
addiction with medication-assisted therapy using
buprenorphine. For eligibility for inclusion in the
prospective group, patients had to meet the same
criteria as described for the retrospective group.
With informed consent, we recruited a prospective
group for the implementation of the ERAS protocol
over a 6-month period. Patients were excluded from
the study if any one of the above-mentioned criteria
were not met.
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We then conducted a retrospective evaluation
of medical records for several data points.
These included: patient demographics, medical
comorbidities, gravidity, parity, postoperative
pain scores, postoperative complications, length
of stay (LOS), postoperative care charges, and IV
buprenorphine use during hospitalization. Routine
patient care also included the collection of urine
drug screens. The administration of all postoperative
drugs began when the patient left the operative
suite, as recorded by the nursing staff.
Mean pain scores served as the primary outcome.
On the day of surgery and postoperative days 1,
2 and 3, the mother-baby nurse recorded pain
scores on a Likert scale of 0-10 with 0 representing
no pain and 10 representing severe pain. The goal
at our institution was for the patient to meet a
pain score of 3 or less. Because other institutions
use the measure of a pain score of 4 or less, both
data points were recorded. We also measured
several secondary outcomes, including the amount
of IV buprenorphine used, LOS, nausea and/or
vomiting that required the use of anti-emetics
as well as hospital and pharmacy charges. These
charges included the cost of the local anesthetic
used intraoperatively as well as the charges for
medications used to control pain and nausea and/
or vomiting post operatively. A unique identifier
was given to every patient. The master code
for these identifiers was securely stored on a
password-protected computer. The retrospective
pre-implementation data and the prospective postimplementation data was compared using the Fisher
Exact test and the Mann Whitney U test. Because
data collection was recorded as part of routine
postpartum documentation, blinding of patients,
providers, and staff was virtually impossible.
However, care was taken to ensure that the research
staff did not interact with the patient following
informed consent, except as medically necessary
for routine obstetric and gynecological care. Our
study protocol was approved by the Institutional
Review Board who found it to be exempt from full
review due to the low risk that implementing the
protocol posed to the research subjects. Informed
consent was also waived for those subjects in the
retrospective cohort. The authors of this study do
not have any financial disclosures.
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RESULTS
Seventeen patients met inclusion criteria and were
included in the MARC cohort retrospective control
group. Eleven patients met inclusion criteria for the
prospective ERAS group for analysis. Due to the lowrisk nature of the study, none of the eligible patients
declined participation in the study. As shown in
Table 1, overall mean age was 30.5 years with a range
of 23-41 years and a standard deviation of 4.5 years.
Mean BMI was 30.9kg/m2 with a range of 20-42kg/
m2 and a standard deviation of 6.3kg/m2. The ERAS
group had a higher obesity rate (34.0% versus 28.4%,
p<0.01), however the distribution among the various
classes of obesity were similar. There were more
smokers in the ERAS group 82 versus 71 percent
(p<0.05). All patients in both the retrospective and
prospective groups were on 8mg of sublingual
buprenorphine twice daily preoperatively.
Pregnancy demographics, surgical characteristics
and the comorbidities of hypertension and diabetes
mellitus were similar between the groups. All urine
drug screens were only appropriately positive for
buprenorphine.
Overall pain scores were 27% lower in the ERAS
group (2.95 versus 4.04, p<0.05), as shown in Table
2. 100 percent of patients in the ERAS group met the
pain score goal of 4 or less versus 53% in the control
group (p<0.05). Likewise, 55% of the ERAS patients
versus 18% of the control group (p<0.05) met the
pain score goal of 3 or less (odds Ratio 5.6, 95% CI
1.00-31.3). The odds ratio for the pain goal of 4 or
less could not be calculated as 100 percent of the
ERAS group met this goal.
Similarly, ERAS patients had a lower incidence of
days with significant pain, 5 or higher, at 47 versus
64 percent (p=0.29) and lower incidence of days
with a severe pain score, 7 or higher, at 0 versus
12 percent (p=0.70), although these did not reach
statistical significance. Likewise, ERAS subjects had
a lower proportion of those who reported persistent
pain of 5 or greater (0 versus 18 percent, p=0.21)
and persistent severe pain of 7 or greater (0 versus
6 percent, p=0.61), however these did not reach
statistical significance.
As shown in Table 3, overall IV buprenorphine
use was 51% lower in the ERAS group when
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TABLE 1. Demographic and Surgical Characteristics (n=28)

TABLE 2. Primary Outcomes (n=28)
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compared to the control group, however, this
did not reach statistical significance (0.53mg
versus 1.08mg, p=0.18). Although not statistically
significant, patients were more likely to go without
IV buprenorphine entirely (45 versus 24 percent,
p=0.22). The range of opioid use in the control
group was 0mg to 4.2mg with a standard deviation
of 1.3mg. The range of opioid use in the ERAS group
was 0mg to 1.8mg with a standard deviation of
0.7mg. While not statistically significant, patients
were less likely to need a breakthrough antiemetic
at 9 versus 29 percent (p=0.21). Day 2 discharge rate
was higher in the ERAS group at 36 versus 6 percent,
but likewise did not reach statistical significance
(p=0.15). Pharmacy charges were $603 lower ($1581
versus $2184, p<0.01). Overall hospital charges were
$1589 lower ($10106 versus $11695, p<0.01).
None of the patients abandoned the protocol to
return to traditional pain control methods. None of
the patients in either the retrospective or prospective
groups took narcotics aside from buprenorphine.
With regard to the liposomal bupivacaine, none
of the patients reported allergy, wound infection,
injection site reaction or any other complications.
Despite early ambulation and early catheter removal,
we did not have any adverse events such as urinary
retention or falls. All patients completed the study as
no patients withdrew consent.
TABLE 3. Secondary Outcomes Patients (n=28)

DISCUSSION
Treating opioid addicted patients represents
a special challenge. The goal is to avoid excess
narcotics to prevent relapse while still adequately
treating postsurgical pain so as to help prevent
patients from self-medicating. Our protocol was
associated with a 27% reduction in mean pain
scores. Patients in the ERAS group were 5.6 times
more likely to reach the pain goal of 3 or less with
100% of the patients reaching a mean pain score of
4 or less despite all of the control patients using the
On-Q® bupivacaine system. We observed a lower
incidence of persistent severe pain in the ERAS,
however this did not reach statistical significance.
Our protocol appeared to be associated with
dramatic reductions in IV buprenorphine use at 51%,
however this did not reach statistical significance.
This statistic was underpowered for this outcome
due to the large variability. A secondary MannWhitney test showed to have 80% power with an
alpha of 0.05 to detect an opioid reduction of 51%
was 130 patients per group due to the variability in
IV buprenorphine use, which was not feasible for this
pilot study. Given the price difference between the
On-Q® system and liposomal bupivacaine, and lower
utilization of expensive intravenous acetaminophen
and intravenous buprenorphine, this protocol was
associated with a marked reduction in pharmacy
charges as well as overall
hospital charges.
This study examines
a unique population
in that 29-73% of the
subjects are obese,
26-36% of patients are
tobacco users, and the
subjects come from an
area highly addicted
to opioids. This is the
first study to address
pain management in
patients who struggle
with addiction and who
are on maintenance
therapy. This study is
among the first that
evaluates the safety
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and efficacy of liposomal bupivacaine after cesarean
delivery. The higher proportion of patients who use
tobacco in the ERAS group may have increased the
IV buprenorphine use in the ERAS group, as tobacco
use is associated with higher levels of narcotic use.15
However, its relationship to buprenorphine utilization
is unclear and likely did not significantly alter our
results. While the intrinsic validity characteristics
demonstrate the lack of randomization, a
preponderance of the patient-specific characteristics
that increase surgical difficulty were similar among
the groups.
Our study design is a unique ambispective design
containing both a retrospective, before intervention,
and a prospective, after intervention, component.
Although blinding was impossible due to the nature
of the ERAS protocol intervention, a significant
amount of attention was given to avoiding bias in
the data collection process. The language used to
obtain informed consent was carefully chosen to
avoid artificial lowering of pain scores due to patient
bias. To protect against bias from the research
staff, we took care to avoid interacting with the
research subjects beyond providing their necessary
and routine care. To ensure accuracy of pain
measurements, the nurses were instructed to record
pain scores the same way for all patients. In order to
avoid artificially lowering pain scores, all patients had
similar quantities of opioids offered to them. Due
to the heavily Caucasian population that our facility
serves, we were unable to draw any meaningful
conclusion regarding the effect of the ERAS protocol
on minorities.
Our study is a pilot study, with a relatively small
sample (n=28); a larger and sufficiently powered
study would require a multi-year and multi-center
approach. Patients who underwent surgery earlier in
the day would logically have a longer postoperative
day 0 and thus use more opioids. However, this
discrepancy would have a limited impact as an
additional few hours of postoperative time would
not account for the significant difference seen
between the groups. Our study was not designed,
nor intended to compare the efficacy of On-Q® and
liposomal bupivacaine, rather it was designed to
compare a pain management protocol that utilizes
liposomal bupivacaine to a pain management
protocol that utilizes On-Q®.
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Liposomal bupivacaine with an abdominal binder,
scheduled oral acetaminophen and ibuprofen
along with intravenous buprenorphine as needed
for breakthrough pain are a safe alternative to
traditional methods for patients who are undergoing
treatment for opioid addiction with buprenorphine
after non-emergent cesarean delivery after 34
weeks. Our protocol appears to be associated with
a 27 percent reduction in pain scores and 51 percent
reduction in IV buprenorphine use. This study shows
the promise of liposomal bupivacaine and enhanced
recovery protocols in reducing pain and opioid use
postoperatively. Further prospective and larger
clinical trials are warranted.
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